Clinical Trials Logo

Clinical Trial Summary

There are over 50 million people living with dementia, and by 2050, the number is expected to rise to 152 million worldwide. Mitochondrial dysfunction in the brain of MCI and AD patients is gaining prominence as a potential mechanism and thus treatment target. However, an effective therapy targeting mitochondrial function, is still missing. Photobiomodulation (PBM), is an innovative noninvasive technique that delivers transcranial near infrared light to the brain. PBM is thought to play a key role in enhancing mitochondrial function [especially in tissues with a high number of mitochondria (e.g.,brain)], by reducing oxidative stress and increasing ATP levels. PBM can be safely administered to awake outpatients and does not require general anesthesia or surgical implantation. Recent animal studies, and case studies suggest that PBM is a promising therapy for AD. However, due to the lack of placebo controls and objective blood and neuroimaging biomarkers, the effectiveness and mechanism of action of PBM (via enhancing mitochondrial function) in AD remains to be studied. Objectives: The investigators aim to evaluate cognitive changes and neural correlates associated with PBM in early amnestic MCI (aMCI) during a pilot feasibility study. Participants who meet study criteria will undergo a 6-week trial of home-used PBM using the Neuro Rx Gamma 6days/week, 20 minutes per session (n=20). All patients will undergo clinical and cognitive assessment, blood sample collection, and structural and resting state functional MRI scans in two timepoints; pre and post treatment. The longitudinal nature of the study will allow investigation of the PBM effect and its' neural correlates in aMCI via enhancement of mitochondrial function. The present study provides a unique opportunity to investigate the mitochondrial and neural mechanisms that may be involved in prevention or delay of cognitive decline in aMCI.


Clinical Trial Description

The experimental intervention will be the Vielight Neuro RX Gamma photobiomodulation device. The device uses 5 light emitting diodes (810nm wavelength). Diodes are placed on the skull at equidistance as well as intranasally to target relevant brain areas. No significant heat is generated, allowing for a sham device which will be indistinguishable from the intervention to the subjects. All subjects will be treated in 20 min sessions once daily for 6 days/week for 6 weeks. Subjects/caregivers will be taught to use the device at home and maintain a treatment diary. 20 min sessions of treatment (or sham) administered 6 days/week for 6 weeks by the subject. Baseline (T0) and 6-week (T2): 2 visits per subject pre and post treatment (at baseline, 6-week) for the following assessments: Mini-Mental State Examination (MMSE), CVLT Long delayed free recall, TMT B, TMT A, BVMT-R, Stroop neuropsychological screening, Pittsburgh sleep quality index, Beck's depression inventory, QOL-AD (Quality of life) , Mild Behavioral Impairment Checklist (MBI-C), Lactate, lactate/pyruvate blood test, Structural and functional MRI , One visits at week 3 (remote or in person) for safety assessment. Safety Endpoints: SAEs regardless of device causality, Device-related AEs, Rates of epistaxis and nasal infection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05563298
Study type Interventional
Source Unity Health Toronto
Contact Corinne Fischer, MD
Phone 416-864-5320
Email Corinne.Fischer@unityhealth.to
Status Recruiting
Phase N/A
Start date March 28, 2023
Completion date March 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04779671 - Effects of the Fully Immersive VR Cognitive Training Based on Leisure Activities for the Elderly With MCI and SCD. N/A
Recruiting NCT04466735 - BRain Energy Activation With Ketones to Prevent Alzheimer's Disease Phase 2
Enrolling by invitation NCT06135740 - Impact of Nutrition, Sleep, and Physical Activity on Intellectual Function and Muscle Mass in Older Adults N/A
Recruiting NCT03189485 - Tau PET Imaging in the NACC Study Cohort
Recruiting NCT06402370 - Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia
Active, not recruiting NCT03069391 - The Interactive Physical and Cognitive Exercise System N/A
Recruiting NCT05460468 - Neuromodulation of Memory in Aging N/A
Completed NCT04095377 - Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
Recruiting NCT05771064 - Promoting In-Home Activities at a Memory & Aging Clinic Phase 1
Completed NCT03224988 - Bilateral Brain Dynamics in Cognition and Aging
Recruiting NCT06335836 - The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
Completed NCT05380284 - Senior Driving Simulation Training for Subjective Cognitive Decline and Mild Cognitive Impairment N/A
Recruiting NCT04897464 - Validation Study of a New Digital Treatment Test N/A
Active, not recruiting NCT02380573 - Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease Phase 2
Completed NCT04243642 - PJ-011726 IntelliSpace Cognition MCI Study
Recruiting NCT01830998 - Early Detection of Cognitive Dysfunction in Diabetes N/A
Recruiting NCT03900936 - Detecting Dementia Earlier
Recruiting NCT06264557 - Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment N/A
Not yet recruiting NCT06223438 - Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.
Not yet recruiting NCT05682469 - Effects and Mechanism of the Fully Immersive Virtual Reality Cognitive Training Based on Leisure Activities N/A